Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2008 Jan-Mar;22(1):94-7.
doi: 10.1097/WAD.0b013e31815a9dcc.

Health behavior changes after genetic risk assessment for Alzheimer disease: The REVEAL Study

Serena Chao  1 , J Scott Roberts, Theresa M Marteau, Rebecca Silliman, L Adrienne Cupples, Robert C Green
Affiliations
Randomized Controlled Trial

Health behavior changes after genetic risk assessment for Alzheimer disease: The REVEAL Study

Serena Chao et al. Alzheimer Dis Assoc Disord. 2008 Jan-Mar.

Abstract

Risk information for Alzheimer disease (AD) may be communicated through susceptibility gene disclosure, even though this is not currently in clinical use. The REVEAL Study is the first randomized clinical trial of risk assessment for AD with apolipoprotein E (APOE) genotype and numerical risk estimate disclosure. We examined whether APOE genotype and numerical risk disclosure to asymptomatic individuals at high risk for AD alters health behaviors. One hundred sixty-two participants were randomized to either intervention (APOE disclosure) or control (no genotype disclosure) groups. Subjects in both groups received numerical lifetime risk estimates of future AD development based on sex and family history of AD. The intervention group received their APOE genotype. Subjects were informed that no proven preventive measures for AD existed and given an information sheet on preventative therapies under investigation. Participants who learned they were epsilon 4 positive were significantly more likely than epsilon 4 negative participants to report AD-specific health behavior change 1 year after disclosure (adjusted odds ratio: 2.73; 95% confidence interval: 1.14, 6.54; P=0.02). Post hoc analyses revealed similar significant associations between numerical lifetime risk estimates and self-report of AD-specific health behavior change. Despite lack of preventive measures for AD, knowledge of APOE genotype, numerical lifetime risk, or both, influences health behavior.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
Participants' progression through the REVEAL Study.
See this image and copyright information in PMC

References

    1. Farrer LA, Cupples LA, Haines JL, et al. Effects of age, sex and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease: a meta-analysis. J A M A. 1997;278:1349–1356. - PubMed
    1. Green RC, Cupples LA, Go R, et al. Risk of dementia among white and African American relatives of Alzheimer's disease patients. J A M A. 2002;287:329–336. - PubMed
    1. Post SG, Whitehouse PJ, Binstock RH, et al. The clinical introduction of genetic testing for Alzheimer's disease: an ethical perspective. J A M A. 1997;277:832–836. - PubMed
    1. Green R, Clarke V, Thompson V, et al. Early detection of Alzheimer's disease: methods, markers and misgivings. Alzheimer Dis Assoc Disord. 1997;11(suppl 5):S1–S5. - PubMed
    1. Roberts JS, LaRusse SA, Katzen H, et al. Reasons for seeking genetic susceptibility testing among first-degree relatives of people with Alzheimer's disease. Alzheimer Dis Assoc Disord. 2003;17:86–93. - PubMed

Publication types

Substances